Host adaptiveimmune responses have been described in melanoma with a main focus on melanomaspecific T cell responses [8], [9], and supported by successful case scenarios usingimmunotherapeutic strategies such as dendritic cell vaccines, adoptive T celltherapies, and CTLA4 monoclonal antibodies [7], [10], [11], [12], [13]. This evidence concerns the gene CTLA4 and melanoma.